Schrödinger $SDGR
Recent IPO Schrödinger extends its existing collaboration with AstraZeneca, 
AZN, aimed at enhancing the former's Free Energy Perturbation technology for the optimization of key properties of biologics, particularly binding affinity. As technically, it is rising and needs to break the trendlines and hold above $45.
AZN, aimed at enhancing the former's Free Energy Perturbation technology for the optimization of key properties of biologics, particularly binding affinity. As technically, it is rising and needs to break the trendlines and hold above $45.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.